It's tough to imagine a buyout/merger price under .50 cents IMO, even if the RD trial bombs. Think of it - with all the pharmas out there having at least a modest interest in AMPA upmodulation (see list below), and Cortex's monopoly on the low impact platform (confirmed at the recent SHM), plus the liklihood that Cortex's high impacts will be the only ones to ever achieve the required ...
